BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230123
DTEND;VALUE=DATE:20230125
DTSTAMP:20260516T045532
CREATED:20221007T091733Z
LAST-MODIFIED:20221007T091733Z
UID:35438-1674432000-1674604799@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:SAE Media Group’s 2nd Annual Conference \nTransdermal and Microneedle Drug Delivery \nJanuary 23 – 24\, 2023 | London\, UK \nwww.transdermal-microneedle-delivery.co.uk/pharmajournalistel \n————————————————————————- \nSAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference\, taking place on the 23rd to 24th January 2023. \n \nThe 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design. Regulation of transdermal delivery systems will be another key theme addressed\, in combination with clinical trial optimization. Engage in the latest innovations in device design\, development and formulation\, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease. \nThe two-day agenda offers you peer-to-peer networking with CEO’s\, Senior Vice presidents\, Directors\, Heads of Product Development and many more. \nBENEFITS OF ATTENDING: \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nWHO SHOULD ATTEND: \n\nDrug-Delivery Device Developers\nMicroneedle Device Developers\nTransdermal Delivery Developers\nMicroarray Patch Developers\nMedical Device Engineers\nPrimary Packaging Material Designers\nSecondary Packagers\nSmart Device Developers\nTraining Device Developers\nDevice-Safety Solution Providers\nDrug Developers\nTransdermal Drug Product Developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\n\nRegistrations can be made on the event website at: www.transdermal-microneedle-delivery.co.uk/ \nTargeted Keywords \nTransdermal and Microneedle Drug Delivery\, transdermal\, drug development\, regulatory guidelines\, pharmaceutical industry\, drug delivery\, therapeutic sectors\, vaccines\, Parenteral administration\, combination products\, primary packaging\, sterile injectables\, connectivity\, human factors\, autoinjectors
URL:https://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045532
CREATED:20220826T121137Z
LAST-MODIFIED:20220831T191624Z
UID:35017-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 2nd Annual mRNA-Based Therapeutics Summit Europe is the only end-to-end mRNA-dedicated meeting in Europe and the largest gathering for mRNA professionals outside of the United States. \nBuilt with biopharmaceutical industry insights\, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nHear from 35+ pioneering large pharma\, biotech\, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry. \nWith more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization\, cell-specific payload expression\, and durability\, there has never been a more pivotal time to join European biopharma experts and discuss the following topics. \n-Emerging cell-enhancing or protein replacement therapies based on mRNA \n-Optimization of analytical and quality control protocols \n-Durability\, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines \n-Enhancement of formulation\, process development and manufacturing processes \n-Need for clear regulatory path to support the technology whilst enabling speed to market \nTo learn more\, download your copy of the full event guide including all speakers and their session details: https://ter.li/tholw0
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit-europe/
LOCATION:TBC – Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:mailto:info@hansonwade.com?subject=2nd Annual mRNA-Based Therapeutics Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045532
CREATED:20221011T104423Z
LAST-MODIFIED:20221208T115612Z
UID:35446-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:DDR Inhibitors Summit 2023
DESCRIPTION:The 6th DDR Inhibitors Summit is taking place in-person for the first time in 3 years in Boston\, MA this January 24 – 26\, 2023. \nThe DNA damage response inhibitor space only continues to grow\, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN\, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy. \nThe scope of this year’s meeting is to bring together leading minds in DDRi drug development to exploring these strategies and aim to address issues related to emerging DDR inhibitor resistance and maximizing efficacy\, as well as addressing the biggest challenge in the space right now\, toxicity. \nThe 3-day meeting will consist of a comprehensive overview of the DDR space\, with over 30+ world class speakers sharing insights preclinical updates\, progress in the clinic\, solutions to overcoming toxicity and improving patient selection. \nDon’t miss out on hearing from the best in the field on how to overcome toxicity and resistance during drug design as well as in the clinic\, to maximize efficacy and propel your DDR inhibitors to success. \nTo know more visit: https://ter.li/40qr50
URL:https://www.pharmajournalist.com/event/ddr-inhibitors-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045532
CREATED:20221110T115619Z
LAST-MODIFIED:20221110T115619Z
UID:35763-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd HFpEF & HCM Drug Discovery & Development Summit
DESCRIPTION:The 2nd HFpEF & HCM Drug Discovery & Development Summit is the definitive industry forum dedicated to propelling drug discovery and development across emerging therapeutics including cell and gene therapies and the implementation of precision medicine. \n \nShake hands with industry pioneers prioritizing the development of therapeutic treatments to complement the new standard of care with SGLT2 inhibitors and understand how you can leverage advances in biomarkers for early detection of drug efficacy and clinical trial updates to inform your strategic decisions. \nJoin 80+ biopharma experts in research\, cardiovascular\, rare disease and precision medicine as they analyze the HFpEF patient population and translational drug development pathway to achieve new commercially viable and clinically accepted therapeutics. \nTo know more visit: https://bit.ly/3EjK5H3
URL:https://www.pharmajournalist.com/event/2nd-hfpef-hcm-drug-discovery-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR